Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment

Table 1 Characteristics of included RCT studies

Study (year)	Center	Location	Type of RVO	Primary endpoint	NO. of eyes			Age (year)			Sex (male/female)			Patient characteristics
Study (year)	Center	Location	Type of RVO	Primary endpoint	IVR 0.5 mg	IVR 0.3 mg	control	IVR 0.5 mg	IVR 0.3 mg	control	IVR 0.5 mg	IVR 0.3 mg	control	Patient characteristics
CRUISE (2010)	M	United States (95site)	CRVO	6 m	130	132	130	65.4 ± 13.1	69.7 ± 11.6	65.4 ± 13.1	80/50	71/61	72/58	1) Age > 18 y
														2) BCVA between 73 and 24 ETDRS letters
														3) RVO duration within 12 months
														4) CFT ≥ 250 μm
ROCC (2010)	M	Norway (4 sites)	CRVO	6 m	16		16	NA		NA	NA		NA	1) Age > 50 y
														2) BCVA between 73 and 6 ETDRS letters
														3) CFT ≥ 250 μm
BRAVO (2010)	M	United States (93site)	BRVO	6 m	131	134	132	65.2 ± 12.7	66.6 ± 11.2	65.2 ± 12.7	71/60	67/67	74/58	1) Age > 18 y
														2) BCVA between 73 to 24 ETDRS letters
														3) RVO duration within 12 months
														4) CFT ≥ 250 μm
Tan (2014)	M	Australia (5site)	BRVO	12 m	15		21	69.6 ± 11.6		66.7 ± 10.7	8/7		9/12	1) Age > 18 y
														2) BCVA between 68 to 20
														3) RVO duration between 6 weeks to 9 months.
														4) CFT ≥ 250 μm

RCT = prospective randomized controlled; RVO = retinal vein occlusion; IVR = intravitreal ranibizumab; M = multicenter; CRVO = central retinal vein occlusion; BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; CFT = central foveal thickness; NA = not available; BRVO = branch retinal vein occlusion.

ISSN: 1471-2415